Walgreens Boots Alliance, Inc. (WBA) — 2023Q3 FY2023 Earnings Call Analysis

Healthcare $300M Light, Now Asked to Swing $700M in One Year

Management missed the US Healthcare base year by $300M in nine months and is guiding to a $600-650M profit next year.

Thesis: The retail pharmacy core is genuinely fine: 100bps of retail gross margin expansion, Boots 13% comp, international AOI +30% constant currency, $1B+ of defined FY24 savings. But the equity is a leveraged bet on US Healthcare swinging from a $340M loss to a $600-650M profit while absorbing $290M of COVID decay and a $260M sale-leaseback step-down, funded by a balance sheet that is not yet inside the 4.75x Moody's investment-grade target. The segment already came in $300M light against expectations set nine months ago.

Verdict: SHORT — Conviction: MEDIUM

Catalyst: Q4 sequential adjusted EBITDA improvement in US Healthcare, which management explicitly guided to: 'rapid correction actions are underway, and we expect to drive sequential adjusted EBITDA improvement in the fourth quarter and beyond.'

Key Risk: VillageMD panel building and Summit integration inflect on schedule, US Healthcare losses narrow in Q4, and the $800M FY24 transformational savings land. Then low-teens core AOI growth before offsets reaches the bottom line and the stock re-rates.

The Tell: Analyst Eric Percher asked how the FY24 healthcare outlook compares to the view six months ago. Management answered unprompted with the miss: 'the base year has come in about 300 light versus the original expectations at nine months ago,' citing 'some slowness at building patient panels at Village.' They volunteered the size of their own forecasting error in the same breath as a $600-650M FY24 profit target.

Detected Patterns

Say/Do Gap: Management projects low-to-mid single digit FY24 AOI growth led by US Healthcare while simultaneously guiding that segment to a $340-380M adjusted EBITDA loss. The segment base year came in ~$300M light versus expectations set nine months ago, and the FY24 bridge requires a $700M+ swing off that miss.
Unsustainable Trend Confidence: Two of the largest FY23 tailwinds reverse in FY24: $290M of COVID contribution and a $260M sale-leaseback step-down that runs out entirely after next year. Management's own math shows core growth must cover $550M+ in identified headwinds, and they concede AOI growth will outpace EPS due to higher tax and non-controlling interest.
Inventory Divergence: Front-of-store inventory runs above 90 days, pharmacy above 30 days, both called 'quite high' by management. Only 40% of the identified $1B working capital opportunity is captured and the micro-fulfillment and perpetual inventory rollouts are described as multi-year. Meanwhile leverage is outside the 4.75x Moody's target.
Margin Expansion Engine: Retail gross margin expanded over 100 basis points for a second consecutive quarter while sales grew 8.9% constant currency, and the transformational cost program raised its cumulative target for the sixth time to $4.1B with $800M booked into FY24. The retail core is compounding, not just cutting.
Clean Answers: Management quantified the guidance cut to the cent: 23-point COVID headwind from 16M down to 12.5M vaccinations, 3-point ABC drag, 20-25c consumer realignment, 12% full-year and 23% Q4 tax rate, and a $4 normalized EPS bridge. No deflection on the tough questions.

Friction Level: MODERATE_FRICTION — Both sides agree the healthcare ramp is behind plan and the FY24 bridge carries $550M+ in identified headwinds. Disagreement is whether $1B+ of controllable cost savings plus 100bps retail gross margin expansion absorbs them, or whether the equity is just a leveraged call on VillageMD panel economics.

Report not found

The report data is no longer available. Please return to the archive.

Healthcare $300M Light, Now Asked to Swing $700M in One Year | Silicon Signal